Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AFFY .051 someone wants out. Big sale. Just picked up more at .051
You may be comparing apples to oranges. Each company has it's own fingerprint. I do agree our company has value but what the market thinks remains to be seen.
$EGXP .03 to $2.00 so far on merger news. It has $1.6 million NOL’s. $AFFY has $480 million NOL’s! Can’t wait till it’s AFFY’s turn for news!
From the looks of Affy they are going to walk it down some more. I'll sit on the sidelines for a while until then. When the Sept deadline comes I'll make a decision.
There is no doubt in my mind that stock will run hard going forward. I imagine .20 or higher which would give $FBCD a $500 million market cap. I just hope $AFFY updates their financials so we could have a $500 million market cap here too (which would equate to about $6.75 for $AFFY)
Hopefully you make huge money on it then move some more money over here for more gains.
Everybody has speculation on what the impact will be for the NOL'S for FBCd. What you're saying is speculation. Affy may prove to be more beneficial but at this time it's all speculation.
I just mentioned $AFFY on that board. FBCD’s NOLs will be of little use due to ownership change. AFFY never actually had an ownership change so all $500 million can be used.
I can’t wait till something happens here. We will be well off!
Check out FBCd. It's an example of what can happen here. They are happy about a 27mil carry forward. We have 500 mil here!!
I totally agree. We have plenty of time. So much potential here. Dollars per share IMO
Still keeping an eye on it. No rush for any parties involved. Could have easily sold out for profit. I believe they are holding out for the best possible deal.
Still have a 500k bid but I know what you mean. $AFFY will eventually be multiple dollars IMO
I don't really trust those numbers they put up. Could be a ploy. I won't be selling any of my shares at 6. Worth way more. The stock can be revived at any time so not worried about grey's.
$AFFY - someone has a huge 500,000 bid in at .06. Maybe something happens soon? That’s a lot of money for a stock that could go to greys if not reporting by September!
Interesting info. Till then I'll keep adding.
$AFFY...I’ve been doing some digging. CEO Couchman has hired this guy to do his filings and whatnot. Looks like he deals with mergers and the like:
https://www.olshanlaw.com/attorneys-Adam-Finerman.html
Here is a recent MYRX filing that has this guys name along with the well known company he works for on it:
https://sec.report/Document/0000921895-20-002102/
He is spending decent money by using this firm. My guess is for possible merger or acquisition for both $AFFY and $MYRX
Here is a list of the firms clients:
https://www.olshanlaw.com/clients.html
I don’t know of any other company that has a massive $480 million NOL’s. It would be perfect for a company that is already profitable since under the Jobs act, I believe they can go back 5 years to offset those profits. I could be wrong though.
I'll keep pecking like a chicken with it's feed until then. This would make an excellent merger acquisition for someone.
I agree 100%. I am hoping this is the year that it happens. Every time I think about the remaining shares getting DTC approved a couple months ago, the more I think we close to seeing this get utilized.
Now is the time to take advantage of this asset. Been sitting on this one for 10 years so no need for me to get impatient.
$AFFY - CEO Couchman has to be close to finding someone to utilize its massive $480 million NOL’s. That’s a huge tax savings for any profitable company.
Our big day is coming soon IMO
Remember these. I use to think it might be a slight chance they would reinstate the drug. Then I stuck around for the NOL'S.
From the old $AFFY 10-K regarding Omontys:
If Takeda decides to reintroduce OMONTYS, which is highly uncertain, we are eligible to receive royalties and (i) potential commercial milestone payments totaling up to $180.0 million which consists of the following: (a) $10.0 million is payable upon the first commercial sale after reintroduction of OMONTYS in the U.S.; (b) $10.0 million and another $10.0 million relates to U.S. sales-based milestones, and (c) $150.0 million relates to sales-based milestones in amounts as previously disclosed outside of the U.S. but now including Japan as a result of the Amendment and (ii) a potential development milestone payment of $5.0 million payable either upon regulatory approval in the E.U. or Japan. The royalties are tiered in the range of 13% to 17% with respect to net sales in the U.S. and in the range of 13% to 24% depending on the level of net sales by Takeda worldwide outside of the U.S.
“ February 2013, the FDA had received 19 reports of severe anaphylactic reactions occurring within 30 min of a patient’s first dose. Indeed, among 19,428 patients who received intravenous peginesatide in a postapproval study, there were seven deaths due to anaphylaxis. The cause of this was not clear, but the preparation used in preapproval clinical trials was a single-dose vial, whereas the product used in dialysis units in the United States was a multidose vial with preservatives. Regardless, the manufacturer voluntarily withdrew peginesatide from further clinical use, and this drug is no longer available.”
I think AFFY should bring back Peginesatide but in single dose vials. Then we would be north of $20 a share IMO. Seemed like the drug was fine in single dose vials
Sounds good to me!!
Very good sign indeed. Would like to see a .10 break and stay above that till news/filings come out.
Just a matter of time till we get some type of news here. I can’t wait for it. We will all do well with our AFFY shares
Bid/Ask tightening up. Good sign!
I think it's September. Money talks though. If a company contacts them and makes some arrangements that will buy more time.
Is the due date around the end of September? I was reading where the SEC was recommending that companies start the filing process by June so that it would be approved and whatnot by the deadline.
We know that Couchman and his BOD has a lot of experience in this field so it should be a fairly easy task for them to complete on time if not early
He's on the clock whether he likes it or not. We will get an answer. He can't prolong it any longer.
I’m here to wait as long as it takes. Definitely have a strong feeling it will be this year for some reason.
Also, some people frown when Couchman doesn’t respond to the emails that are sent to him. There are reasons for this. First, he won’t say anything that isn’t already in old filings. Also, having too many shareholders would trigger a mandatory filing updating event which would be costly.
It will be a lot cheaper to be able to go through the basic reporting method through OTC markets.
That's the thing about the market. It's just passing time till the fun starts. I think they call it, hurry up and wait.
Wonder what is in store for AFFY this week? With the recent change in DTC approved shares its making me think something is up. There usually isn’t a reason for a dark otc stock to go through the process of getting DTC approval unless something like a merger or purchase is going to happen.
Gotta read in between the lines here
He's been sitting on this one for a long time. He must have big plans.
Jonathan Couchman is one of very few professional and well known CEO’s of OTC shell stocks. If worthlesss AWGI has a market cap of $24 million then AFFY should be trading at .40 to have same value.
AFFY will get utilized soon IMO
Just staying patient. Looking for a lot more than .10.
$AFFY lots of buys today so far. Nice to see .10 again. First time since March 1st
If it moves before any announcements that may be an idication news is coming.
Let’s see if we can break past .10 this week! I want to see mid .20’s again soon. Then onto $1+ if filings updated IMO
How much of the 219k volume was you?
We will be noticed. They have companies out here just doing mergers of pennies. There is a rush to get in before new rules set in. Never seen a rush like this before.
Doing a little shopping on Friday. Good deals today!
$AFFY volume surge. 145k shares traded
That will be nice when that starts happening.
Nice volume today so far. Can’t wait for $AFFY to get noticed
Communication with shareholders is very important now. That is also one of the changes. No longer will CEO's be able to sit in the shadows.
Will do. Hopefully he is busy getting AFFY and MYRX to Pink current.
Let me know if he replies.
I emailed Couchman to remind him about the new reporting requirements. I’m sure he is already on top of it.
Will be nice to get updated information in the coming months assuming he complies with the new rules
Lots of buys today. Just need to break past the .10 resistance. I’m excited for this one. With the recent OS changes with the DTC, I think something is in the works
Followers
|
62
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2292
|
Created
|
03/24/08
|
Type
|
Free
|
Moderators |
http://www.affymax.com/
http://finance.yahoo.com/q/ks?s=AFFY
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. Its lead product candidate includes Hematide, a synthetic peptide-based erythropoiesis stimulating agent, which is designed to treat anemia associated with chronic kidney disease and cancer. The company is conducting phase II clinical trials of Hematide in dialysis patients, predialysis patients, cancer patients on chemotherapy and patients with PRCA. It is also developing a pipeline of peptide based drug candidates, including Adeptide, a peptide based, non-injectable erythropoiesis stimulating agent; the Innotide program that comprises a family of peptide based drug candidates for use in the area of tissue protection in preclinical models of stroke, myocardial infarct, and renal injury; and Angiotide, a synthetic peptide for treating cancer by blocking angiogenesis, or blood vessel formation in tumors. Affymax has strategic alliances with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide; EntreMed, Inc. for preclinical research of Angiotide; and Nektar Therapeutics AL, Corporation. The company was founded in 2001 and is based in Palo Alto, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |